Ferdinandus J, Barbato F, Chodyla M, Fendler WP, et al. Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. J Nucl Med 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
PMID: 32532926